Our bankruptcy laws have long provided a safe harbor for troubled medicalpractices and businesses to reorganize, refinance, and begin the turnaroundto profitability free from pressure by their creditors. Now, new bankruptcylaws loom on the horizon that will severely reduce that safe harbor while,at the same time, make it more difficult for both practices and businessesto deal with suppliers and patients/customers who are in, or about to enterinto, bankruptcy.
Jonathan E. Rosenberg, MD, discusses the FDA approval of perioperative durvalumab plus enfortumab vedotin and considerations for treatment selection in cisplatin-ineligible MIBC.
Jessica Feehan, NP-C, discusses the expanding role of APPs in urology, from clinical leadership and procedures to care coordination and treatment initiation.
Sam S. Chang, MD, MBA, discusses treatment selection after BCG failure, including bladder-sparing options, cystectomy considerations, and the need for sequencing data.